Research and Markets has announced the addition of the "Global CRISPR/Cas9 Market Outlook 2022" report to their offering.
It is anticipated that the global CRISPR/Cas9 market will cross US $1.5 Billion by 2022.
The growth of the market is likely to be driven by expanding drug discovery applications and increasing research related activities for exploring CRISPR/Cas9 therapeutic applications.
The report, Global CRISPR/Cas9 Market Outlook 2022, provides an insight into the current and future prospective of this market. This report covers the major opportunities in this area, and drivers that have impact on the market. The report also discusses some of the challenges currently faced by the market.
The major application areas of CRISPR/Cas9 include cell line engineering, genetic engineering, CRISPR plasmid development, human stem cells, gene library development and producing GM organisms or crops. Cell Line Engineering is the largest area of application of CRISPR/Cas9, followed by Genetic Engineering. This large share can be attributed to extensibility and multiplexity of CRISPR/Cas9 in modifying the multiple sites within the mammalian genome. The genetic engineering market employing CRISPR/Cas9 is expected to witness the highest growth in 2016-2022. This growth is likely to be driven by reduction of evolutionary time in comparison to previous gene editing tools, such as Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs).
The last segment of the report is entirely devoted to profiling leading companies of the CRISPR/Cas9 industry, including some major players like Thermo Fisher Scientific, Lonza, Agilent Technologies, GenScript, Editas Medicine, Horizon Discovery, etc.
This segment provides access to the financials, product portfolio, and recent developments of these companies. This segment also discusses the strengths and weaknesses of key players in this industry. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global CRISPR/Cas9 market.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Introduction to CRISPR/Cas9 Genome Editing
4. Market Dynamics
4.1 Market Drivers
4.1.1 Expanding Drug Discovery Market
4.1.2 Surging Demand for Synthetic Genes
4.1.3 Rising Prevalence of Genetic Disorders
4.1.4 Increasing Investments
4.2 Market Challenges
4.2.1 Ethical Issues Concerning Misuse of CRISPR Gene Editing Tool
4.2.2 Presence of Alternative Gene Editing Tools
4.3 Market Opportunities
4.3.1 Increasing Usage of CRISPR Gene Editing for Gene Surgery
4.3.2 Enhancing Plant Immunity with CRISPR/Cas9
4.3.3 Emerging Contract Research Market for CRISPR/Cas9
5. Global CRISPR/Cas9 Market Outlook to 2022
6. CRISPR/Cas9 Market by Application
6.1 Cell Line Engineering
6.2 Genetic Engineering
6.3 CRISPR Plasmid
6.4 Gene Library
6.5 Human Stem Cells
6.6 Genetically Modified (GM) Organisms/Crops
7. CRISPR/Cas9 Market by End User
7.1 Academic & Research Institutes
7.2 Pharma/Biotech Companies
8. CRISPR/Cas9 Market by Geography
9. Mergers and Collaborations
10. Company Profiles
10.1 GE Healthcare
10.2 Thermo Fisher Scientific, Inc.
10.3 Agilent Technologies, Inc.
10.6 Horizon Discovery Group plc.
10.7 Editas Medicine, Inc.
10.8 CRISPR Therapeutics
10.9 Caribou Biosciences, Inc.
10.10 Intellia Therapeutics, Inc.
10.11 Integrated DNA Technologies
10.12 OriGene Technologies, Inc.
10.13 Transposagen Biopharmaceuticals, Inc.
10.14 New England Biolabs Inc.
For more information about this report visit http://www.researchandmarkets.com/research/z9bqcj/global
View source version on businesswire.com: http://www.businesswire.com/news/home/20161018006821/en/Business Wire
Last updated on: 19/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.